Table 1 Clinical characteristics of patients with IgAN and IgAVN included in the present study and control subjects

Number of patients and controls

6

6

6

6

5

Median age (years) (range)

42 (16‒71)

67 (22‒76)

71 (36‒78)

60 (34‒74)

53 (45‒77)

Male:female

3:3

2:4

2:4

2:4

1:4

Chance proteinuria and/or hematuria, n

6

0

Urinary abnormalities after the onset of purpura, n

6

6

Progressive renal dysfunction, n

1

3

0

1

Edema, n

0

5

0

2

Hypertension, n

2

4

1

4

RAS-I/CCB/SARA/AB/BB/DU, n

2/1/0/0/0/0

1/3/1/1/0/0

1/1/0/0/0/0

3/2/0/1/1/2

Purpura, n

6

6

Arthralgia, n

0

1

Abdominal pain, n

0

1

Median proteinuria (g/day or g/gCr) at biopsy (range)

0.4 (0.1–2.8)

5.9 (4.1‒10.0)

3.6 (0.2‒7.9)

2.0 (0.5‒6.4)

0.7 (0.1‒0.9)

Median serum albumin (g/dL) (range)

4.0 (3.5‒4.7)

2.5 (2.2‒2.8)

3.5 (1.8‒4.3)

3.6 (2.5‒3.9)

4.3 (3.5‒4.5)

Nephrotic syndrome, n

0

6

1

2

Median serum Cr (mg/dL) (range)

0.89 (0.50‒1.85)

1.13 (0.62‒2.07)

0.79 (0.48‒1.18)

0.76 (0.59‒2.10)

0.67 (0.60‒0.90)

Median eGFR (mL/min/1.73 m²) (range)

77.8 (32.6‒109.3)

55.6 (22.4‒73.6)

66.0 (34.5‒98.4)

59.2 (25.1‒92.8)

72.1 (66.9‒81.6)

Median serum IgA (mg/dL) (range)

439 (213‒921)

322 (189‒528)

305 (254‒410)

330 (214‒382)